Nordic Nanovector ASA Results for the Second Half and Full Year 2022

OSLO, Norway, Feb. 28, 2023 /PRNewswire/ — Nordic Nanovector ASA (OSE: NANOV) (“Nordic Nanovector” or the “Company”) announces its results for the second half and full year 2022. A presentation by Nordic Nanovector’s interim CEO & CFO, Ludvik Sandnes will be held in-person today in Oslo and webcast live beginning at 8:30am CET – details below.… Continue reading Nordic Nanovector ASA Results for the Second Half and Full Year 2022

Volvo Cars to open new software development facility in Poland

Volvo Cars is to open a brand-new Tech Hub in Krakow, Poland’s second-largest city. The facility will be a key software development centre and play a crucial role in Volvo’s strategic ambition to be a fully electric brand by 2030 and a leader in new technology, not least through in-house software development. The Tech hub… Continue reading Volvo Cars to open new software development facility in Poland

Volvo Cars to open new software development facility in Poland

Volvo Cars is to open a brand-new Tech Hub in Krakow, Poland’s second-largest city. The facility will be a key software development centre and play a crucial role in Volvo’s strategic ambition to be a fully electric brand by 2030 and a leader in new technology, not least through in-house software development. The Tech hub… Continue reading Volvo Cars to open new software development facility in Poland

Biologics License Application for lecanemab designated for Priority Review by China National Medical Products Administration

STOCKHOLM, Feb. 28, 2023 /PRNewswire/ — BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the Biologics License Application (BLA) for lecanemab (brand name in the U.S.: LEQEMBI™), an investigational anti-amyloid beta (Aβ) protofibril antibody has been designated for Priority Review by the National Medical Products Administration (NMPA) in China. The Priority Review… Continue reading Biologics License Application for lecanemab designated for Priority Review by China National Medical Products Administration

Biologics License Application for lecanemab designated for Priority Review by China National Medical Products Administration

STOCKHOLM, Feb. 28, 2023 /PRNewswire/ — BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the Biologics License Application (BLA) for lecanemab (brand name in the U.S.: LEQEMBI™), an investigational anti-amyloid beta (Aβ) protofibril antibody has been designated for Priority Review by the National Medical Products Administration (NMPA) in China. The Priority Review… Continue reading Biologics License Application for lecanemab designated for Priority Review by China National Medical Products Administration

Biologics License Application for lecanemab designated for Priority Review by China National Medical Products Administration

STOCKHOLM, Feb. 27, 2023 /PRNewswire/ — BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the Biologics License Application (BLA) for lecanemab (brand name in the U.S.: LEQEMBI™), an investigational anti-amyloid beta (Aβ) protofibril antibody has been designated for Priority Review by the National Medical Products Administration (NMPA) in China. The Priority Review… Continue reading Biologics License Application for lecanemab designated for Priority Review by China National Medical Products Administration

Greenbrier mourns the passing of board member David L. Starling

LAKE OSWEGO, Ore., Feb. 27, 2023 /PRNewswire/ — The Greenbrier Companies, Inc. (NYSE:GBX) today remembers Board member David L. Starling, who passed away at the age of 73. The Company extends its condolences to his family, particularly his wife Candace and his two sons, Zach and Jeff, all great supporters of his many endeavors, including… Continue reading Greenbrier mourns the passing of board member David L. Starling

Mitsubishi Corporation invests in Swedish Biofuels

STOCKHOLM, Feb. 28, 2023 /PRNewswire/ — Swedish Biofuels AB announced today an investment by Mitsubishi Corporation to jointly accelerate commercial deployment of clean renewable fuels using Swedish Biofuels advanced alcohol to jet (ATJ) technology. The technology produces fully formulated sustainable aviation fuel (FFSAF) from a variety of biogenic feedstocks. Swedish Biofuels FFSAF is different from… Continue reading Mitsubishi Corporation invests in Swedish Biofuels

Mitsubishi Corporation invests in Swedish Biofuels

STOCKHOLM, Feb. 28, 2023 /PRNewswire/ — Swedish Biofuels AB announced today an investment by Mitsubishi Corporation to jointly accelerate commercial deployment of clean renewable fuels using Swedish Biofuels advanced alcohol to jet (ATJ) technology. The technology produces fully formulated sustainable aviation fuel (FFSAF) from a variety of biogenic feedstocks. Swedish Biofuels FFSAF is different from… Continue reading Mitsubishi Corporation invests in Swedish Biofuels

Mitsubishi Corporation invests in Swedish Biofuels

STOCKHOLM, Feb. 28, 2023 /PRNewswire/ — Swedish Biofuels AB announced today an investment by Mitsubishi Corporation to jointly accelerate commercial deployment of clean renewable fuels using Swedish Biofuels advanced alcohol to jet (ATJ) technology. The technology produces fully formulated sustainable aviation fuel (FFSAF) from a variety of biogenic feedstocks. Swedish Biofuels FFSAF is different from… Continue reading Mitsubishi Corporation invests in Swedish Biofuels